Literature DB >> 16616284

Common side effects of anti-EGFR therapy: acneform rash.

Rebecca Sipples1.   

Abstract

OBJECTIVES: To review the general toxicity profile of EGFR-targeted therapies and the management of the most common side effect, skin toxicity. DATA SOURCES: Research articles.
CONCLUSION: The most common side effect of anti-EGFR therapy is skin toxicity, which is generally mild to moderate, but may be severe in up to 18% of patients. Appearance of more severe rash has been correlated with better treatment outcomes. Skin toxicity is generally manageable with standard topical or systemic antibiotics and anti-inflammatory agents. Rash does not warrant treatment discontinuation; however, when using TKIs, the combination of rash and severe diarrhea may require treatment cessation. IMPLICATIONS FOR NURSING PRACTICE: Patients and nurses need to be well informed about the expected side effects of anti-EGFR therapy and appropriate management techniques. Patient education prior to beginning therapy and proactive intervention at the first signs of skin toxicity are key to successful management.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616284     DOI: 10.1016/j.soncn.2006.01.013

Source DB:  PubMed          Journal:  Semin Oncol Nurs        ISSN: 0749-2081            Impact factor:   2.315


  20 in total

1.  Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer.

Authors:  Zhongsheng Peng; Jiayan Chen; Cinthia B Drachenberg; Jean-Pierre Raufman; Guofeng Xie
Journal:  J Biol Chem       Date:  2019-04-09       Impact factor: 5.157

2.  Rash management and treatment persistence of cancer patients treated with epidermal growth factor receptor inhibitors in the Truven MarketScan® research database.

Authors:  Lei Chen; Jacqueline Brown; Dale Quentin Marmaduke; Carlos Mayo; Gerrit Grau; Yiu-Keung Lau; Coleman K Obasaju
Journal:  Support Care Cancer       Date:  2018-02-08       Impact factor: 3.603

3.  Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions.

Authors:  Iris Amitay-Laish; Michael David; Salomon M Stemmer
Journal:  Oncologist       Date:  2010-08-13

4.  Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis.

Authors:  Shoude Zhang; Jia Chen; Hua Jiang; Haina Ma; Beibei Yang
Journal:  Eur J Clin Pharmacol       Date:  2012-01-10       Impact factor: 2.953

5.  Rash rates with egfr inhibitors: meta-analysis.

Authors:  N Mittmann; S J Seung
Journal:  Curr Oncol       Date:  2011-04       Impact factor: 3.677

6.  Assessment of Tumor Response and Resection Rates in Unresectable Colorectal Liver Metastases Following Neoadjuvant Chemotherapy with Cetuximab.

Authors:  S P Somashekhar; K R Ashwin; Shabber S Zaveri; Amit Rauthan; Poonam Patil
Journal:  Indian J Surg Oncol       Date:  2015-07-05

7.  Presenilin/gamma-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression.

Authors:  Yun-wu Zhang; Ruishan Wang; Qiang Liu; Han Zhang; Francesca-Fang Liao; Huaxi Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-07       Impact factor: 11.205

8.  Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations.

Authors:  B Melosky; R Burkes; D Rayson; T Alcindor; N Shear; M Lacouture
Journal:  Curr Oncol       Date:  2009-01       Impact factor: 3.677

9.  Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodies (Our Experience With Cetuximab).

Authors:  Rossella De Luca; Gianluca Lo Coco; Raffaele Addeo; Silvia Ileana Sara Fattoruso; Annunziata Auriemma; Roberta Paci; Ornella Mistretta; Maria Stella Epifanio; Angela Salvato; Alberto D'Agostino; Giuseppe Cicero
Journal:  World J Oncol       Date:  2021-07-10

Review 10.  Mucin in cancer: a stealth cloak for cancer cells.

Authors:  Dong-Han Wi; Jong-Ho Cha; Youn-Sang Jung
Journal:  BMB Rep       Date:  2021-07       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.